[go: up one dir, main page]

MX2017012188A - Inhibidores de beta-secretasa 1 (bace1). - Google Patents

Inhibidores de beta-secretasa 1 (bace1).

Info

Publication number
MX2017012188A
MX2017012188A MX2017012188A MX2017012188A MX2017012188A MX 2017012188 A MX2017012188 A MX 2017012188A MX 2017012188 A MX2017012188 A MX 2017012188A MX 2017012188 A MX2017012188 A MX 2017012188A MX 2017012188 A MX2017012188 A MX 2017012188A
Authority
MX
Mexico
Prior art keywords
present
bace1 inhibitors
bace1
alzheimer
therapeutic
Prior art date
Application number
MX2017012188A
Other languages
English (en)
Inventor
Woltering Thomas
Uwe Peters Jens
Dolente Cosimo
Obst Sander Ulrike
Bartels Bjoern
Haap Wolfgang
Guba Wolfgang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017012188A publication Critical patent/MX2017012188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula I, que presenta una actividad inhibidora de BACE1, su preparación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticamente activas. Los compuestos activos de la presente invención resultan útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer.
MX2017012188A 2015-03-20 2016-03-16 Inhibidores de beta-secretasa 1 (bace1). MX2017012188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15160101 2015-03-20
PCT/EP2016/055649 WO2016150785A1 (en) 2015-03-20 2016-03-16 Bace1 inhibitors

Publications (1)

Publication Number Publication Date
MX2017012188A true MX2017012188A (es) 2017-12-15

Family

ID=52780400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012188A MX2017012188A (es) 2015-03-20 2016-03-16 Inhibidores de beta-secretasa 1 (bace1).

Country Status (18)

Country Link
US (4) US10047081B2 (es)
EP (1) EP3271355B1 (es)
JP (1) JP6674960B2 (es)
KR (1) KR20170129745A (es)
CN (1) CN107406440B (es)
AU (1) AU2016236402B2 (es)
BR (1) BR112017015474A2 (es)
CA (1) CA2979113A1 (es)
CL (1) CL2017002229A1 (es)
CO (1) CO2017007691A2 (es)
CR (1) CR20170426A (es)
IL (1) IL253322A0 (es)
MX (1) MX2017012188A (es)
PE (1) PE20171349A1 (es)
PH (1) PH12017501668A1 (es)
RU (1) RU2712272C2 (es)
SG (1) SG11201707050VA (es)
WO (1) WO2016150785A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017012188A (es) * 2015-03-20 2017-12-15 Hoffmann La Roche Inhibidores de beta-secretasa 1 (bace1).
CN110467611B (zh) * 2018-05-11 2022-09-27 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途
AR115495A1 (es) 2018-06-06 2021-01-27 Syngenta Crop Protection Ag Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2712228C (en) 2008-02-18 2013-04-16 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl amine derivatives
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
US8815881B2 (en) 2010-08-09 2014-08-26 Hoffmann-La Roche Inc. 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
US20120053200A1 (en) 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
US9242943B2 (en) 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8399459B2 (en) 2011-02-02 2013-03-19 Hoffmann-La Roche Inc. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US9067924B2 (en) 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
US8748418B2 (en) 2011-03-18 2014-06-10 Hoffmann-La Roche Inc. 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
US8877744B2 (en) 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
CA2832473A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions, and their use
CN103596939A (zh) * 2011-04-13 2014-02-19 默沙东公司 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
KR20140041590A (ko) 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 [1,3]옥사진
JP2014516063A (ja) 2011-06-07 2014-07-07 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのハロゲン−アルキル−１，３オキサジン
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) * 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
AR089781A1 (es) 2012-01-26 2014-09-17 Hoffmann La Roche Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
US9273042B2 (en) * 2012-05-24 2016-03-01 Hoffmann-La Roche Inc. 5-amino[1,4]thiazines as BACE 1 inhibitors
SG11201407576YA (en) 2012-06-26 2015-03-30 Hoffmann La Roche Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
US9422277B2 (en) * 2012-10-17 2016-08-23 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
EP2948446A1 (en) 2013-01-22 2015-12-02 F. Hoffmann-La Roche AG Fluoro-[1,3]oxazines as bace1 inhibitors
EP2968356B1 (en) 2013-03-15 2018-03-07 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use
WO2014150331A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
US9453034B2 (en) 2013-03-15 2016-09-27 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use
MX2017012188A (es) 2015-03-20 2017-12-15 Hoffmann La Roche Inhibidores de beta-secretasa 1 (bace1).

Also Published As

Publication number Publication date
RU2017134884A3 (es) 2019-07-17
IL253322A0 (en) 2017-09-28
HK1244790A1 (zh) 2018-08-17
JP2018507879A (ja) 2018-03-22
PE20171349A1 (es) 2017-09-13
JP6674960B2 (ja) 2020-04-01
KR20170129745A (ko) 2017-11-27
US10047081B2 (en) 2018-08-14
US11034687B2 (en) 2021-06-15
WO2016150785A1 (en) 2016-09-29
AU2016236402B2 (en) 2019-08-01
EP3271355A1 (en) 2018-01-24
CN107406440A (zh) 2017-11-28
US20200308166A1 (en) 2020-10-01
SG11201707050VA (en) 2017-10-30
US20180319787A1 (en) 2018-11-08
CN107406440B (zh) 2021-05-07
US20190337936A1 (en) 2019-11-07
AU2016236402A1 (en) 2017-07-27
CA2979113A1 (en) 2016-09-29
BR112017015474A2 (pt) 2018-01-30
US10723729B2 (en) 2020-07-28
EP3271355B1 (en) 2020-07-29
CO2017007691A2 (es) 2017-10-20
US10399969B2 (en) 2019-09-03
RU2017134884A (ru) 2019-04-22
CR20170426A (es) 2017-10-23
US20180057485A1 (en) 2018-03-01
PH12017501668A1 (en) 2018-03-19
RU2712272C2 (ru) 2020-01-28
CL2017002229A1 (es) 2018-04-13

Similar Documents

Publication Publication Date Title
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
PH12015502365A1 (en) Bace1 inhibitors
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502156A1 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
NZ755637A (en) Compounds and their use in the treatment of schistosomiasis
PH12017501668A1 (en) Bace1 inhibitors
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
NZ800047A (en) Benzimidazolone derived inhibitors of bcl6
NZ780408A (en) Human plasma kallikrein inhibitors
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека